NHS Scotland spin-out company Aurum Biosciences is seeking to appoint a new Chair as the company enters an exciting new stage in its development.
Aurum is gearing up to start its first phase 2 study in the treatment of acute ischaemic stroke patients with its lead product ABL-101, which was discovered from technology coming out of the NHS. A major advance in Aurum’s manufacturing strategy is underway, and the company is also seeking corporate partnerships, and is in the process of raising new investment to fund the next studies on this condition.
Business angel syndicate TRICAPITAL led the initial funding round in 2015, bringing together private investment from the UK and USA, alongside Scottish Enterprise’s Scottish Investment Bank and The Wellcome Trust. During the last 3 years, the company has made major advances under the current leadership, and is now looking to strengthen the team with the appointment of a new Chair.
The ideal candidate will have the following profile:
An appropriate incentive arrangement will be agreed with the successful candidate.
Please apply to Jim McGuire (CEO) at email@example.com, enclosing CV and covering letter explaining your interest in and suitability for the role.
To find out more about this exciting company and ABL-101, visit the Aurum Biosciences website.
Watch this video for an overview of Aurum Biosciences and ABL-101:
Comments are closed.